A narrative review suggests that several common conditions, including Type 2 Diabetes, heart failure with preserved ejection fraction, and chronic kidney disease, are actually parts of one shared process. This concept is called the unified cardiometabolic disease continuum. Instead of treating these as isolated issues, this framework views them as different stages of a single underlying problem involving metabolism and organ health.
The review identifies several factors that drive this linked condition. These include problems with fat tissue, inflammation, and changes in the gut microbiome. These factors can lead to damage in both the heart and the kidneys over time. The study highlights how these shared mechanisms contribute to conditions like high blood pressure and liver disease as well.
Specific medications, such as GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone, are noted for their role in managing this continuum. Because these conditions are linked, doctors may use these treatments to address multiple issues at once. This review is a summary of existing literature rather than a new clinical trial, so it provides a framework for understanding how these diseases interact.
